Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1117 participants.

Also called NCT01215955

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,117 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01215955
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Austria, Brazil, Canada, Croatia, Denmark, France, Lithuania, Mexico, Poland, Puerto Rico, Romania, Russia, South Africa (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01215955. Randomized; no masking; primary purpose treatment. Start 2010-12 (registry gives no type); primary completion 2013-01 (actual). Results posted on 2014-02-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes
Acronym
AUTONOMY
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Insulin lispro
Intervention (Drug)
Glargine
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01215955
Content hash
6331be4891c1469d6a81731d3295c69e3a32e5b4a6d2531fc18bbc3cb995b5f0